Gabriel Lopez‐Berestein

43.9k total citations · 3 hit papers
349 papers, 21.1k citations indexed

About

Gabriel Lopez‐Berestein is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Gabriel Lopez‐Berestein has authored 349 papers receiving a total of 21.1k indexed citations (citations by other indexed papers that have themselves been cited), including 222 papers in Molecular Biology, 102 papers in Cancer Research and 59 papers in Oncology. Recurrent topics in Gabriel Lopez‐Berestein's work include MicroRNA in disease regulation (64 papers), RNA Interference and Gene Delivery (56 papers) and Cancer-related molecular mechanisms research (42 papers). Gabriel Lopez‐Berestein is often cited by papers focused on MicroRNA in disease regulation (64 papers), RNA Interference and Gene Delivery (56 papers) and Cancer-related molecular mechanisms research (42 papers). Gabriel Lopez‐Berestein collaborates with scholars based in United States, Egypt and China. Gabriel Lopez‐Berestein's co-authors include Anil K. Sood, Bülent Özpolat, George A. Călin, Cristian Rodriguez‐Aguayo, Kapil Mehta, Robert L. Coleman, R T Mehta, Rajesha Rupaimoole, Ana M. Tari and María Angélica Cortez and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of the American Chemical Society.

In The Last Decade

Gabriel Lopez‐Berestein

343 papers receiving 20.6k citations

Hit Papers

MicroRNAs in body fluids—the mix of hormones and biomarkers 2010 2026 2015 2020 2011 2010 2016 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. MicroRNAs in body fluids—the mix of hormones and biomarkers
    2011 1.2k citations Gabriel Lopez‐Berestein, Anil K. Sood et al. profile →
  2. RNA interference in the clinic: challenges and future directions
    2010 654 citations Robert L. Coleman, Gabriel Lopez‐Berestein et al. profile →
  3. miRNA Deregulation in Cancer Cells and the Tumor Microenvironment
    2016 532 citations Rajesha Rupaimoole, George A. Călin et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gabriel Lopez‐Berestein United States 78 13.2k 6.1k 3.8k 2.4k 1.9k 349 21.1k
Behzad Baradaran Iran 70 11.7k 0.9× 5.3k 0.9× 4.1k 1.1× 3.3k 1.4× 903 0.5× 648 21.2k
Adriana Albini Italy 81 10.2k 0.8× 4.6k 0.7× 7.0k 1.8× 4.0k 1.7× 1.3k 0.7× 396 22.9k
R. L. Juliano United States 75 11.9k 0.9× 2.3k 0.4× 4.4k 1.2× 2.1k 0.9× 828 0.4× 232 21.8k
Stefano Fais Italy 70 11.7k 0.9× 6.4k 1.0× 2.4k 0.6× 4.4k 1.8× 1.4k 0.7× 217 17.3k
Kaichun Wu China 80 11.4k 0.9× 5.9k 1.0× 4.1k 1.1× 2.0k 0.8× 3.0k 1.6× 622 21.3k
Yasufumi Kaneda Japan 79 11.8k 0.9× 2.4k 0.4× 2.2k 0.6× 3.4k 1.4× 2.1k 1.1× 470 24.5k
Yehuda G. Assaraf Israel 70 9.4k 0.7× 2.5k 0.4× 5.7k 1.5× 1.0k 0.4× 973 0.5× 262 17.0k
Min Wang China 56 9.0k 0.7× 5.5k 0.9× 2.7k 0.7× 2.4k 1.0× 1.3k 0.7× 702 16.6k
Takashi Tsuruo Japan 89 16.6k 1.3× 2.8k 0.5× 12.4k 3.2× 2.1k 0.9× 1.3k 0.7× 446 27.7k
Erwei Song China 72 14.3k 1.1× 10.1k 1.6× 6.4k 1.7× 4.4k 1.9× 1.4k 0.8× 227 22.7k

Countries citing papers authored by Gabriel Lopez‐Berestein

Since Specialization
Citations

This map shows the geographic impact of Gabriel Lopez‐Berestein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gabriel Lopez‐Berestein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gabriel Lopez‐Berestein more than expected).

Fields of papers citing papers by Gabriel Lopez‐Berestein

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gabriel Lopez‐Berestein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gabriel Lopez‐Berestein. The network helps show where Gabriel Lopez‐Berestein may publish in the future.

Co-authorship network of co-authors of Gabriel Lopez‐Berestein

This figure shows the co-authorship network connecting the top 25 collaborators of Gabriel Lopez‐Berestein. A scholar is included among the top collaborators of Gabriel Lopez‐Berestein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gabriel Lopez‐Berestein. Gabriel Lopez‐Berestein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Noh, Kyunghee, Duc‐Hiep Bach, Hyun Jin Choi, et al.. (2020). The hidden role of paxillin: localization to nucleus promotes tumor angiogenesis. Oncogene. 40(2). 384–395. 19 indexed citations
2.
Miyake, Takahito, Sunila Pradeep, Emine Bayraktar, et al.. (2020). NRG1/ERBB3 Pathway Activation Induces Acquired Resistance to XPO1 Inhibitors. Molecular Cancer Therapeutics. 19(8). 1727–1735. 8 indexed citations
3.
Yang, Hailing, Weiqun Mao, Cristian Rodriguez‐Aguayo, et al.. (2018). Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability. Clinical Cancer Research. 24(20). 5072–5084. 32 indexed citations
4.
Hu, Qianghua, Takeshi Hisamatsu, Monika Haemmerle, et al.. (2017). Role of Platelet-Derived Tgfβ1 in the Progression of Ovarian Cancer. Clinical Cancer Research. 23(18). 5611–5621. 63 indexed citations
5.
Wagner, Michael J., Rahul Mitra, Mark J. McArthur, et al.. (2017). Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA). Molecular Cancer Therapeutics. 16(6). 1114–1123. 101 indexed citations
6.
Hu, Zhongyi, Lingegowda S. Mangala, Zachary E. Stine, et al.. (2017). MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels. Cancer Research. 78(1). 64–74. 91 indexed citations
7.
González-Villasana, Vianey, Enrique Fuentes‐Mattei, Cristina Ivan, et al.. (2015). Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer. Clinical Cancer Research. 21(9). 2127–2137. 63 indexed citations
8.
Tucker, Susan L., Kshipra M. Gharpure, Shelley M. Herbrich, et al.. (2014). Molecular Biomarkers of Residual Disease after Surgical Debulking of High-Grade Serous Ovarian Cancer. Clinical Cancer Research. 20(12). 3280–3288. 68 indexed citations
9.
Cortez, Valerie, Monica Mann, Takayoshi Suzuki, et al.. (2012). Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer. Breast Cancer Research. 14(4). R108–R108. 65 indexed citations
10.
Shao, Longjiang, İbrahim Tekedereli, Jianghua Wang, et al.. (2012). Highly Specific Targeting of the TMPRSS2/ERG Fusion Gene Using Liposomal Nanovectors. Clinical Cancer Research. 18(24). 6648–6657. 48 indexed citations
11.
Vivas‐Mejía, Pablo E., Cristian Rodriguez‐Aguayo, Hee‐Dong Han, et al.. (2011). Silencing Survivin Splice Variant 2B Leads to Antitumor Activity in Taxane-Resistant Ovarian Cancer. Clinical Cancer Research. 17(11). 3716–3726. 58 indexed citations
12.
Kim, Hye‐Sun, Hee Dong Han, Guillermo N. Armaiz-Peña, et al.. (2011). Functional Roles of Src and Fgr in Ovarian Carcinoma. Clinical Cancer Research. 17(7). 1713–1721. 62 indexed citations
13.
Landen, Charles N., Blake W. Goodman, Ashwini A. Katre, et al.. (2010). Targeting Aldehyde Dehydrogenase Cancer Stem Cells in Ovarian Cancer. Molecular Cancer Therapeutics. 9(12). 3186–3199. 322 indexed citations
14.
Spannuth, Whitney A., Lingegowda S. Mangala, Rebecca L. Stone, et al.. (2010). Converging Evidence for Efficacy from Parallel EphB4-Targeted Approaches in Ovarian Carcinoma. Molecular Cancer Therapeutics. 9(8). 2377–2388. 33 indexed citations
15.
Pan, Xue, Thiruvengadam Arumugam, Tameyoshi Yamamoto, et al.. (2008). Nuclear Factor-κB p65/relA Silencing Induces Apoptosis and Increases Gemcitabine Effectiveness in a Subset of Pancreatic Cancer Cells. Clinical Cancer Research. 14(24). 8143–8151. 105 indexed citations
16.
Mangala, Lingegowda S., Jansina Y. Fok, Yvonne G. Lin, et al.. (2008). Clinical and Biological Significance of Tissue Transglutaminase in Ovarian Carcinoma. Cancer Research. 68(14). 5849–5858. 88 indexed citations
17.
Fernández, Ariel, Ángela Sanguino, Zhenghong Peng, et al.. (2007). Rational Drug Redesign to Overcome Drug Resistance in Cancer Therapy: Imatinib Moving Target. Cancer Research. 67(9). 4028–4033. 32 indexed citations
18.
Tari, Ana M., Soo-Jeong Lim, Mien‐Chie Hung, Francisco J. Esteva, & Gabriel Lopez‐Berestein. (2002). Her2/neu induces all-transretinoic acid (ATRA) resistance in breast cancer cells. Oncogene. 21(34). 5224–5232. 63 indexed citations
19.
Yoo, G., Mien‐Chie Hung, Gabriel Lopez‐Berestein, et al.. (2001). Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer.. PubMed. 7(5). 1237–45. 87 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Behzad Baradaran Breakdown of academic impact, for papers by Adriana Albini Breakdown of academic impact, for papers by R. L. Juliano Breakdown of academic impact, for papers by Stefano Fais Breakdown of academic impact, for papers by Kaichun Wu Breakdown of academic impact, for papers by Yasufumi Kaneda Breakdown of academic impact, for papers by Yehuda G. Assaraf Breakdown of academic impact, for papers by Min Wang Breakdown of academic impact, for papers by Takashi Tsuruo Breakdown of academic impact, for papers by Erwei Song
Rankless by CCL
2026